Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety and Tolerability of Subcutaneous Ianalumab in Chinese Adults With Autoimmune Diseases
NCT06411639Phase 1Withdrawn
- Sponsor
- Novartis
- Start
- Nov 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of ianalumab in Sjögren's syndrome and systemic lupus erythematosus (SLE), sponsored by Novartis. Primary endpoints: Area Under the Curve calculated to the end of a dosing interval at steady-state, Observed maximum blood concentration and 1 more. Planned start Nov 2024; status: withdrawn.
02
Drugs
ianalumab
03
Conditions
Sjögren's syndromesystemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06411639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06411639.